$ATOM

Atomera Inc

CIK:0001420520|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 158	$ 0	$ 169	$ 4
Cost of revenue	(26)	(62)	(152)	(62)
Gross (loss) margin	132	(62)	17	(58)
Operating expenses
Research and development	3,287	3,004	6,744	6,259
General and administrative	3,167	2,048	5,500	4,136
Selling and marketing	437	141	856	265
Total operating expenses	6,891	5,193	13,100	10,660
Loss from operations	(6,759)	(5,255)	(13,083)	(10,718)
Other income (expense)
Interest income	172	234	369	504
Accretion income	178	0	235	6
Interest expense	(1)	(18)	(5)	(39)
Other income, net	74	72	75	71
Total other income (expense), net	423	288	674	542
Net loss	$ (6,336)	$ (4,967)	$ (12,409)	$ (10,176)
Net loss per common share, basic	$ (0.17)	$ (0.17)	$ (0.34)	$ (0.34)
Net loss per common share, diluted	$ (0.17)	$ (0.17)	$ (0.34)	$ (0.34)
Weighted average number of common shares outstanding, basic	38,647	30,397	36,961	30,321
Weighted average number of common shares outstanding, diluted	38,647	30,397	36,961	30,321

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash flows from operating activities
Net loss	$ (6,336)	$ (6,073)	$ (4,967)	$ (5,209)	$ (12,409)	$ (10,176)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization					15	24
Operating lease right of use asset amortization					98	125
Financing lease right of use asset amortization	211		250		422	501
Stock-based compensation	1,741		1,278		3,147	2,287
Net accretion of discounts on available-for-sale securities					(202)	(6)
Loss on asset disposal					2	0
Changes in operating assets and liabilities:
Accounts receivable					0	6
Interest receivable					72	10
Prepaid and other current assets					(163)	(358)
Accounts payable					(39)	173
Accrued expenses					129	(32)
Accrued payroll expenses					468	(679)
Operating lease liability					(37)	(158)
Deferred revenue					(7)	(4)
Net cash used in operating activities					(8,504)	(8,287)
Cash flows from investing activities
Acquisition of property and equipment					(16)	(14)
Purchase of available-for-sale securities					(26,988)	0
Maturity of available-for-sale securities					3,890	1,000
Net cash provided by/(used in) investing activities					(23,114)	986
Cash flows from financing activities
Proceeds from registered direct offering of common stock net of commissions and expenses					23,596	0
Proceeds from at-the-market sale of stock, net of commissions and expenses					3,098	3,199
Proceeds from exercise of stock options					1,280	905
Payments on principal of financing lease					(420)	(555)
Net cash provided by financing activities					27,554	3,549
Net (decrease) in cash and cash equivalents					(4,064)	(3,752)
Cash and cash equivalents at beginning of period		$ 19,210		$ 25,778	19,210	25,778	$ 25,778
Cash and cash equivalents at end of period	$ 15,146		$ 22,026		15,146	22,026	$ 19,210
Supplemental information:
Cash paid for interest					4	39
Cash paid for taxes					$ 0	$ 0

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 15,146	$ 19,210
Short-term investments	23,206	0
Interest receivable	58	54
Prepaid expenses and other current assets	542	338
Total current assets	38,952	19,602
Property and equipment, net	59	60
Security deposit	14	14
Operating lease right-of-use asset	1,128	884
Financing lease right-of-use-asset	70	533
Total assets	40,223	21,093
Current liabilities:
Accounts payable	569	608
Accrued expenses	297	168
Accrued payroll-related expenses	1,118	650
Current operating lease liability	304	147
Current financing lease liability	0	420
Deferred revenue	0	7
Total current liabilities	2,288	2,000
Long-term operating lease liability	860	712
Total liabilities	3,148	2,712
Commitments and contingencies (see Note 9)
Stockholders’ equity:
Preferred stock $0.001 par value, authorized 2,500 shares; none issued and outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock: $0.001 par value, authorized 47,500 shares; 39,024 shares issued and outstanding as of June 30, 2026; and 32,354 shares issued and outstanding as of December 31, 2025	39	32
Additional paid in capital	291,157	260,043
Other comprehensive income (loss)	(18)	0
Accumulated deficit	(254,103)	(241,694)
Total stockholders’ equity	37,075	18,381
Total liabilities and stockholders’ equity	$ 40,223	$ 21,093